Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jenscare Scientific CoHKSE:09877 -1.69%33 Buyback Yield % is 0.01 as of Sep. 07, 2026, which is at its 10-year median of 0.01. GuruFocus rates HKSE:09877 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 326 Medical Devices & Instruments companies, Jenscare Scientific Co ranks better than 63.19% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Jenscare Scientific Co Buyback Yield % Related Terms
Jenscare Scientific Co Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Jenscare Scientific Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:09877 vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Jenscare Scientific Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jenscare Scientific Co Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jenscare Scientific Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Jenscare Scientific Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jenscare Scientific Co (HKSE:09877) has a Buyback Yield % of 0.01 as of Sep. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jenscare Scientific Co and its competitors. This is near median its historical median of 0.01. According to the industry distribution chart, Jenscare Scientific Co ranks #120 out of 326 companies in the Medical Devices & Instruments industry, placing it in the top 36.8%.
Is Jenscare Scientific Co's Buyback Yield % too high?
Jenscare Scientific Co's current Buyback Yield % of 0.01 is near median its 10-year median of 0.01. Based on the distribution chart, Jenscare Scientific Co ranks #120 out of 326 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Jenscare Scientific Co has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Jenscare Scientific Co's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Jenscare Scientific Co ranks #120 out of 326 companies for Buyback Yield %. This puts Jenscare Scientific Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Jenscare Scientific Co and its competitors. Jenscare Scientific Co's current Buyback Yield % is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenscare Scientific Co stock overvalued right now?
Jenscare Scientific Co (HKSE:09877) has a current Buyback Yield % of 0.01. The current Buyback Yield % is 0.01, which is near median its 10-year median of 0.01. Jenscare Scientific Co's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Jenscare Scientific Co (HKSE:09877), the current Buyback Yield % is 0.01 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jenscare Scientific Co Ltd is engaged in the manufacturing, research, and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. Geographically, the company generates the majority of its revenue from the Chinese mainland.
33GF Score
Get the complete analysis for HKSE:09877
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09877 has been successfully added to your 
